Addex Shareholders Appoint Hoyoung Huh and Oleg Nodelman to Board
Addex Pharmaceuticals Ltd announced that its shareholders approved all the proposals of the board of directors at its 2011 annual general meeting (AGM). Hoyoung Huh and Oleg Nodelman have joined the board of directors while Beat Lüthi resigned.
Dr. Hoyoung Huh has been involved in the formation and growth of multiple organizations in the U.S., Europe and Asia. He is currently chairman of the board of directors of both BiPar Sciences Inc. and Geron Corp. He also serves on the board of directors of BayBio, Jennerex Inc. and SciDose LLC. Dr. Huh was BiPar's President and CEO, when he led the merger of BiPar with the French pharmaceutical firm Sanofi-Aventis in 2009. He was previously a member of the board of directors, chief operating officer, and head of the PEGylation business unit at Nektar Therapeutics. A former partner at McKinsey & Company, Dr. Huh holds an M.D. from Cornell University Medical College, a Ph.D. in Genetics/Cell Biology from Cornell University/Sloan-Kettering Institute, and a bachelor's degree in biochemistry from Dartmouth College.
Oleg Nodelman is a portfolio manager at the Biotechnology Value Fund, a biotech focused investment fund founded in San Francisco in 1993. Mr. Nodelman was a consultant with Mercer Management Consulting where he worked closely with senior management on financial and strategic matters. Mr. Nodelman holds a Bachelor of Science in International Affairs and a minor in Science in Technology from the School of Foreign Service at Georgetown University. BVF is a 30% shareholder of Addex.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
